Flag of the European Union EU Clinical Trials Register Help

Clinical trials for NK1 receptor antagonist

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: NK1 receptor antagonist. Displaying page 1 of 1.
    EudraCT Number: 2012-005063-28 Sponsor Protocol Number: Emend2 Start Date*: 2013-10-02
    Sponsor Name:University of Gothenburg
    Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant
    Medical condition: End stage renal disease under treatment with peritoneal dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001900-17 Sponsor Protocol Number: 2020/0431/HP Start Date*: 2022-10-24
    Sponsor Name:DRCI - CHU de Rouen
    Full Title: PILOT STUDY OF THE EFFECT OF A SUBSTANCE P ANTAGONIST, APREPITANT, ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ARTERIAL HYPERTENSION SYNDROME
    Medical condition: Patients with obstructive sleep apnea syndrome with arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10052741 Endocrine and metabolic secondary hypertension HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004912-30 Sponsor Protocol Number: aprepitant1 Start Date*: 2008-07-31
    Sponsor Name:Karolinska Institutet
    Full Title: Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study
    Medical condition: opiate abuse
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039004 Reversal of opiate activity LLT
    9.1 10012346 Dependence on opiates LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001021-22 Sponsor Protocol Number: NKO101287 Start Date*: 2005-02-08
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-002164-26 Sponsor Protocol Number: P04888 Start Date*: 2006-11-10
    Sponsor Name:Schering Plough Research Institute, a division of Schering Corporation
    Full Title: Study of the Efficacy and Safety of SCH619734 in Subjects with Chronic Idiopathic Cough
    Medical condition: Chronic Idiopathic Cough
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000370-31 Sponsor Protocol Number: NKT102260 Start Date*: 2005-05-20
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Ant...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000371-34 Sponsor Protocol Number: NKV20001 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001020-20 Sponsor Protocol Number: NKV101983 Start Date*: 2005-01-25
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title:
    Medical condition: Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) SK (Completed) HU (Completed) AT (Completed) GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 10:01:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA